Role of the kappa-opioid receptor system in stress-induced reinstatement of nicotine seeking in rats

Behav Brain Res. 2014 May 15:265:188-97. doi: 10.1016/j.bbr.2014.02.029. Epub 2014 Feb 28.

Abstract

Rationale: The correlation between stress and smoking is well established. The mechanisms that underlie this relationship are, however, unclear. Recent data suggest that the kappa-opioid system is involved in the mediation of negative affective states associated with stress thereby promoting drug addiction and relapse. Pharmacological treatments targeting the kappa-opioid system and this mechanism may prove to be useful therapeutics for nicotine addiction in the future.

Objectives: We sought to determine whether there was a stress-specific role of the kappa-opioid system in nicotine seeking behavior.

Method: Groups of male Long Evans rats were trained to self-administer nicotine intravenously; their operant responding for nicotine was extinguished prior to tests of reinstatement. Pretreatment with systemic injections of the kappa-opioid receptor (KOR) antagonist nor-binaltorphimine (nor-BNI) was given prior to tests of stress (systemic injections of yohimbine (YOH)) or cue-induced reinstatement of nicotine seeking. Systemic injections of the KOR agonist U50,488 were also given in a test for reinstatement of nicotine seeking.

Results: Nor-BNI pretreatment at 1h and 24h prior to testing was able to block YOH-induced, but not cue-induced reinstatement of nicotine seeking. U50,488 reinstated nicotine seeking behavior in a dose-dependent manner.

Conclusions: These findings support the hypothesis that the kappa-opioid system is involved in relapse to nicotine seeking induced by stress, but not by conditioned cues. KOR antagonists such as nor-BNI may therefore be useful novel therapeutic agents for decreasing the risk of stress-induced drug relapse.

Keywords: Nicotine; Nor-binaltorphimine; Reinstatement; Stress; U50,488; Yohimbine.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer / pharmacology
  • Adrenergic alpha-2 Receptor Antagonists
  • Analgesics, Non-Narcotic / pharmacology
  • Animals
  • Conditioning, Operant / drug effects
  • Drug Administration Schedule
  • Drug Interactions
  • Extinction, Psychological / drug effects
  • Male
  • Naltrexone / administration & dosage
  • Naltrexone / analogs & derivatives
  • Nicotine / administration & dosage*
  • Nicotinic Agonists / administration & dosage*
  • Rats
  • Rats, Long-Evans
  • Receptors, Opioid, kappa / metabolism*
  • Self Administration
  • Stress, Psychological / etiology*
  • Stress, Psychological / prevention & control*
  • Tobacco Use Disorder / complications*
  • Yohimbine / toxicity

Substances

  • Adrenergic alpha-2 Receptor Antagonists
  • Analgesics, Non-Narcotic
  • Nicotinic Agonists
  • Receptors, Opioid, kappa
  • Yohimbine
  • norbinaltorphimine
  • Naltrexone
  • 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer
  • Nicotine